Disease-Specific Indications and Outcomes

Related Resources

Patient Resources

Acute Myeloid Leukemia (AML) - Adult

Recent advances informing clinical decision-making include increasing identification of prognostic genetic markers in AML used to determine the disease risk status and a composite comorbidity/age score for treatment risk stratification. [1-7]

Because of these advances, more is known about which patients are eligible for hematopoietic cell transplantation (HCT) and which are not. In addition, large-scale studies have determined the optimal timing for HCT. As shown in Figure 1, patients with AML transplanted while in first or second complete remission have significantly better outcomes than patients transplanted with advanced disease.

Figure 1. AML Survival, Unrelated Marrow HCT, by Disease Status

AML Survival, Unrelated Marrow HCT, by Disease Status

Download slide

Worldwide, physicians perform more than 7,000 allogeneic transplants for AML, making it the most common and fastest growing indication for allogeneic HCT. [8] As shown in Figure 2, increasing numbers of patients over age 64 years with AML are undergoing HCT, which is due to reduced-intensity conditioning regimens and better post-transplant supportive care.

Figure 2. AML Unrelated HCT, by Age

AML Unrelated HCT, by Age

Download slide

 

For patients with intermediate- and poor-risk cytogenetics, a meta-analysis demonstrated a survival benefit of allogeneic HCT in first complete remission over chemotherapy. [9] Early referral for HCT evaluation for these at-risk patients at an early disease stage can significantly improve survival. [10,11]

The National Marrow Donor Program® (NMDP)/Be The Match® and the American Society for Blood and Marrow Transplantation (ASBMT) have jointly developed guidelines for transplant referral timing based on disease characteristics (see Referral Timing Guidelines section below).

Disease Risk Stratification

Evolving research is altering how cytogenetic and molecular markers are used to guide therapeutic choices in AML. Table 1 shows risk status based on validated cytogenetics and molecular markers from the NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines®) for Acute Myeloid Leukemia.

Table 1. National Comprehensive Cancer Network® (NCCN®) risk status based on validated cytogenetics and molecular abnormalities for AML

 Risk Status Cytogenetics Molecular Abnormalities
 FAVORABLE-RISK Core binding factor: inv (16) or t(16;16) or
 t(8;21) or t(15;17)		 Normal cytogenetics:
 NPM1 mutation in the absence of FLT3-ITD
 or isolated biallelic (double) CEBPA mutation
 INTERMEDIATE-RISK Normal cytogenetics
 +8 alone
 t(9;11)
 Other non-defined 		 

Core binding factor with KIT mutation
Mutated NPM1 and FLT3-ITDhigh
Wild-type NPM1 without FLT3-ITD or with FLT3-ITDlow

(without poor-risk genetic lesions) 
 POOR-RISK Complex (=3 clonal chromosomal abnormalities)
 Monosomal karyotype
 -5, 5q-, -7, 7q-
 11q23 - non t(9;11)
 inv(3), t(3;3)
 t(6;9)
 t(9;22) 		 

Normal cytogenetics:
with FLT3-ITD mutation
TP53 mutation
Mutated RUNX1
Mutated ASXL1
Wild-type NPM1 and FLT3-ITDhigh

 

Adapted with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Myeloid Leukemia V.2.2018 - Sept, 1 2018. © 2018 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines® and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

For patients with intermediate- and poor-risk cytogenetics, a meta-analysis demonstrated a survival benefit of allogeneic HCT in first complete remission over chemotherapy. [9] Early referral for HCT evaluation for these at-risk patients at an early disease stage can significantly improve survival. [10,11]

The National Marrow Donor Program® (NMDP)/Be The Match® and the American Society for Blood and Marrow Transplantation (ASBMT) have jointly developed guidelines for transplant referral timing based on disease characteristics (see "Referral Timing Guidelines" section below).

 

Advances

Recent research provides new data for the clinical management of AML:

  • Molecular markers testing at diagnosis can now influence therapy choices [1-6]
  • Use of the composite comorbidity/age scores (HCT-CI), instead of age alone, is useful for prognostic risk assessment before HCT [7]
  • Age alone is no longer a significant factor affecting overall survival in HCT [12]
  • Clinical data show a survival benefit for allogeneic HCT in Intermediate-Risk AML in first complete remission (CR1) [9]
  • Increasing numbers of older patients meet eligibility requirements for allogeneic HCT because of reduced-intensity HCT [13,14]
  • Survival has improved over time due to better risk stratification, supportive care, and more precise HLA matching [15,16]
  • Unrelated donor transplant outcomes are similar to related donor transplant outcomes [17-19]

Outcomes

Improved Survival Over Time

Transplant outcomes have steadily improved over time, even as increasing numbers of older individuals undergo transplant (Figures 3 and 4). Review outcome data for allogeneic transplantation in adults with AML below. View additional AML slides showing demographic data and transplant trends.

Data in this section have been prepared by CIBMTR® (Center for International Blood and Marrow Transplant Research), our research program.

Figure 3: AML Survival Over Time, Unrelated HCT

AML Survival Over Time, Unrelated HCT

Download slide

Figure 4. AML Survival Over Time, Unrelated HCT

AML Survival Over Time, Unrelated HCT

Download slide

Figure 5. AML Survival, Unrelated PBSC HCT, by Disease Status

AML Survival, Unrelated PBSC HCT, by Disease Status

Download slide

Figure 6. AML Survival, Unrelated HCT, AML patients >55 years

AML Survival, Unrelated HCT, Patients ≥ 55 years

Download slide

Figure 7. AML Survival, Sibling HCT, by Disease Status

AML Survival, Sibling HCT, by Disease Status

Download slide

Figure 8. AML Survival, Unrelated HCT, by Disease Status

AML Survival, Unrelated HCT, by Disease Status

Download slide

Referral Timing Guidelines

These guidelines identify appropriate timing of consultation for transplant based on disease characteristics. [20]

Transplant Consultation Guidelines: Adult AML

High-resolution HLA typing is recommended at diagnosis for all patients

Early after initial diagnosis, all patients with AML including:

  • Primary induction failure
  • Minimal residual disease after initial therapy
  • CR1 - except favorable risk AML [defined as: t(16;16), inv 16, or t(8;21) without c-KIT mutation; t(15;17); normal cytogenetics with NPM1 or isolated biallelic CEBPA mutation and without FLT3-ITD]
  • Antecedent hematological disease (e.g., myelodysplastic syndrome (MDS))
  • Treatment-related leukemia
  • First relapse
  • CR2 and beyond, if not previously evaluated
Download slide (PPT)
View complete Referral Timing Guidelines

References

  1. Patel JP, Gönen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012; 366(12): 1079-1089. Access
  2. Vyas P, Appelbaum FR, Craddock C. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia. Biol Blood Marrow Transplant. 2015; 21(1): 8-15. Access
  3. Röllig C, Bornhäuser M, Kramer M. et al. Allogeneic stem-cell transplantation in patients with NPM1-mutated acute myeloid leukemia: Results from a prospective donor versus no-donor analysis of patients after upfront HLA typing within the SAL-AML 2003 trial. J Clin Oncol. 2015; 33(5): 403-410. Access
  4. Ofran Y, Rowe JM. Genetic profiling in acute myeloid leukaemia – where are we and what is its role in patient management. Br J Haematol. 2013; 160(3): 302-320. Access
  5. Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017; 129(4): 424-447. Access
  6. Schlenk RF, Kayser S, Bullinger L, et al. Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation. Blood. 2014; 124(23): 3441-3449. Access
  7. Sorror ML, Storb RF, Sandmaier BM, et al. Comorbidity-age index: A clinical measure of biologic age before allogeneic hematopoietic cell transplantation. J Clin Oncol. 2014; 32(29): 3249-3256. Access
  8. Gratwohl A, Baldomero H, Aljurf M, et al. Hematopoietic stem cell transplantation: A global perspective. JAMA. 2010; 303(16): 1617-1624. Access
  9. Koreth J, Schlenk R, Kopecky KJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: Systematic review and meta-analysis of prospective clinical trials. JAMA. 2009; 301(22): 2349-2361. Access
  10. Pidala J, Lee SJ, Ahn KW, et al. Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation. Blood. 2014; 124(16): 2596-2606. Access
  11. Lee SJ, Klein J, Haagenson M, et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood. 2007; 110(13): 4576-4583. Access
  12. McClune BL, Weisdorf DJ, Pedersen TL, et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol. 2010; 28(11): 1878-1887. Access
  13. Reshef R, Porter DL. Reduced-intensity conditioned allogeneic SCT in adults with AML. Bone Marrow Transplant. 2015; 50(6): 759-769. Access
  14. Gyurkocza B, Storb R, Storer BE, et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. J Clin Oncol. 2010; 28(17): 2859-2867. Access
  15. Majhail NS, Chitphakdithai P, Logan B, et al. Significant improvement in survival after unrelated donor hematopoietic cell transplantation in the recent era. Biol Blood Marrow Transplant. 2015; 21(1): 142-150. Access
  16. Hahn T, McCarthy PL, Hassebroek A, et al. Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors. J Clin Oncol. 2013; 31(19): 2437-2449. Access
  17. Warlick ED, de Latour RP, Shanley R, et al. Allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia: Similar outcomes regardless of donor type. Biol Blood Marrow Transplant. 2015; 21(2): 357-363. Access
  18. Robin M, Porcher R, Adès L, et al. Matched unrelated or matched sibling donors result in comparable outcomes after non-myeloablative HSCT in patients with AML or MDS. Bone Marrow Transplant. 2013; 48(10): 1296-1301. Access
  19. Saber W, Opie S, Rizzo JD, et al. Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia. Blood. 2012; 119(17): 3908-3916. Access
  20. NMDP/Be The Match and ASBMT Recommended Timing for Transplant Consultation. Download (PDF)